Representative Bilirakis Introduces H.R. 10359 Priority for Pediatric Cures Act
核心洞察
Representative Gus M. Bilirakis introduced H.R. 10359, the Priority for Pediatric Cures Act, on 2026-09-14 with five cosponsors.
The bill would remove the existing sunset date and permanently continue FDA authority to award priority review vouchers for rare pediatric disease (搜索) drugs and biologics.
Vouchers could still be used to accelerate review of a later application or sold and transferred to another company, with no change to FDA approval standards.
Representative Gus M. Bilirakis has introduced H.R. 10359, the Priority for Pediatric Cures Act, received on 2026-09-14 with five cosponsors. The bill makes a narrow change to federal drug law: it would remove the current expiration on the government's authority to grant priority review vouchers for drugs and biologics developed for rare pediatric diseases, keeping the program in place permanently rather than letting it lapse under the existing sunset date.
Under the program, a company with an approved treatment for a qualifying rare pediatric disease (搜索) can receive a voucher from the FDA. That voucher can be used later to speed review of another drug application, or sold or transferred to another company. The vouchers are intended to encourage investment in treatments for very small patient populations that might otherwise be less commercially attractive. The bill would continue allowing qualifying companies to earn vouchers after bringing certain rare pediatric disease products to market and maintain the ability to use or sell them to offset development time and cost.
The legislation does not change FDA approval standards and does not itself approve any specific medicine. It also does not directly alter drug pricing, which diseases qualify, or how vouchers are used beyond making the program permanent. If enacted, it would give drug developers working on rare pediatric diseases longer-term certainty about the voucher pathway.
Source: Quiver Quantitative